Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.

Abstract:

PURPOSE OF REVIEW:Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. RECENT FINDINGS:Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Gentzler RD,Riley DO,Martin LW

doi

10.1007/s11912-020-00969-w

subject

Has Abstract

pub_date

2020-08-15 00:00:00

pages

109

issue

11

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-020-00969-w

journal_volume

22

pub_type

杂志文章,评审
  • Clinical development of siltuximab.

    abstract::Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, we...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0453-1

    authors: Davis CC,Shah KS,Lechowicz MJ

    更新日期:2015-07-01 00:00:00

  • Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

    abstract::The original version of this article, which published in Current Oncology Reports, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer. ...

    journal_title:Current oncology reports

    pub_type: 已发布勘误

    doi:10.1007/s11912-019-0813-3

    authors: Leone JP,Lin NU

    更新日期:2019-05-17 00:00:00

  • Early Cervical Cancer: Current Dilemmas of Staging and Surgery.

    abstract:PURPOSE OF REVIEW:Advances in cervical cancer screening and treatment have resulted in high cure rates in developed countries for early-stage disease. Current research focuses on minimizing morbidity and maximizing quality of life. RECENT FINDINGS:Imaging has been disappointing in identifying small volume metastases. ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0614-5

    authors: Zigras T,Lennox G,Willows K,Covens A

    更新日期:2017-08-01 00:00:00

  • Pediatric palliative care.

    abstract::Pediatric medicine is moving toward a greater appreciation that the delivery of quality medical care involves a partnership including the health care team, the child, and the family. Pediatric medicine now emphasizes the importance of information exchange among these groups. This paper discusses two models for communi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0061-9

    authors: Weidner NJ

    更新日期:2007-11-01 00:00:00

  • Emerging role of proton beam radiation therapy for chordoma and chondrosarcoma of the skull base.

    abstract::Chordomas and chondrosarcomas of the skull base are rare, indolent tumors with a natural history of locally invading their surroundings. Safe, maximal resection is the mainstay of treatment, followed by adjuvant radiation therapy. Even with multimodality therapy, local recurrence remains the most common failure patter...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0052-5

    authors: Nguyen QN,Chang EL

    更新日期:2008-07-01 00:00:00

  • Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

    abstract:PURPOSE OF REVIEW:Immune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0738-2

    authors: Barroso-Sousa R,Ott PA

    更新日期:2018-11-15 00:00:00

  • Chemotherapy for androgen- independent prostate cancer: myth or reality.

    abstract::In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0058-0

    authors: Kelly WK,Slovin SF

    更新日期:2000-09-01 00:00:00

  • When and when not to use testosterone for palliation in cancer care.

    abstract::Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic-pituitary-gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-014-0378-0

    authors: Dev R,Bruera E,Del Fabbro E

    更新日期:2014-04-01 00:00:00

  • New Hypofractionation Radiation Strategies for Glioblastoma.

    abstract:PURPOSE OF REVIEW:Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0616-3

    authors: Azoulay M,Shah J,Pollom E,Soltys SG

    更新日期:2017-09-01 00:00:00

  • New Directions in Vulvar Cancer Pathology.

    abstract:PURPOSE OF REVIEW:The aim of this article is to provide clinicians and pathologists with an understanding of the aetiopathology, pathogenesis and classification of vulval neoplasia and their molecular correlates. RECENT FINDINGS:There is an increased understanding of subcellular changes in vulvar malignancies. These p...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0833-z

    authors: Williams A,Syed S,Velangi S,Ganesan R

    更新日期:2019-08-15 00:00:00

  • Therapeutic advances for glioblastoma multiforme: current status and future prospects.

    abstract::Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/BF02951428

    authors: Robins HI,Chang S,Butowski N,Mehta M

    更新日期:2007-01-01 00:00:00

  • Fertility preservation and management of gonadal failure associated with lymphoma therapy.

    abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0039-6

    authors: Howell SJ,Shalet SM

    更新日期:2002-09-01 00:00:00

  • VEGF inhibition, hypertension, and renal toxicity.

    abstract::The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0242-z

    authors: Hayman SR,Leung N,Grande JP,Garovic VD

    更新日期:2012-08-01 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • Surgical management of spinal mesenchymal tumors.

    abstract::Primary and metastatic spinal mesenchymal tumors are uncommon lesions. Surgical management of these tumors remains a challenge. En bloc wide resection provides the best chance for local tumor control and long-term survival. However, limitations to this technique include technical considerations (including neurovascula...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0036-2

    authors: Mody MG,Rao G,Rhines LD

    更新日期:2006-07-01 00:00:00

  • Human papillomavirus testing for primary cervical cancer screening.

    abstract::With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0081-0

    authors: Runowicz CD,Garozzo S

    更新日期:2008-11-01 00:00:00

  • PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

    abstract::The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0227-y

    authors: Willems L,Tamburini J,Chapuis N,Lacombe C,Mayeux P,Bouscary D

    更新日期:2012-04-01 00:00:00

  • Hepatitis c and lymphoma.

    abstract::Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands. Experimental data further support this hypothesis....

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0090-0

    authors: Silvestri F,Sperotto A,Fanin R

    更新日期:2000-03-01 00:00:00

  • Single-Cell RNA-Sequencing in Glioma.

    abstract:PURPOSE OF REVIEW:In this review, we seek to summarize the literature concerning the use of single-cell RNA-sequencing for CNS gliomas. RECENT FINDINGS:Single-cell analysis has revealed complex tumor heterogeneity, subpopulations of proliferating stem-like cells and expanded our view of tumor microenvironment influenc...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0673-2

    authors: Johnson E,Dickerson KL,Connolly ID,Hayden Gephart M

    更新日期:2018-04-10 00:00:00

  • MEK inhibition in the treatment of advanced melanoma.

    abstract::The RAS-RAF-MEK-ERK pathway is considered to be the most important signal transduction pathway in melanoma, and alterations in this pathway via various genetic mutations, such as BRAF and NRAS mutations, are known to be important drivers of melanomagenesis. As MEK is an essential intermediary kinase protein within thi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0336-2

    authors: Salama AK,Kim KB

    更新日期:2013-10-01 00:00:00

  • Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

    abstract::There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0007-5

    authors: Wesolowski R,Budd GT

    更新日期:2009-01-01 00:00:00

  • Response assessment challenges in clinical trials of gliomas.

    abstract::Accurate, reproducible criteria for determining tumor response and progression after therapy are critical for optimal patient care and effective evaluation of novel therapeutic agents. Currently, the most widely used criteria for determining treatment response in gliomas is based on two-dimensional tumor measurements ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0078-3

    authors: Wen PY,Norden AD,Drappatz J,Quant E

    更新日期:2010-01-01 00:00:00

  • Adjuvant chemotherapy for colon cancer.

    abstract::Colon cancer remains the third most common cancer, and cause of cancer-related death in the United States. Greater public awareness and acceptance of screening programs have contributed significantly to increasingly earlier detection of colon cancer and decreased mortality. Advances made in the understanding of this d...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0007-6

    authors: Kumar SK,Goldberg RM

    更新日期:2001-03-01 00:00:00

  • Translating genomics into clinical practice: applications in lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide and has a poor overall survival across all stages of disease. The recent advancement of gene expression technology addresses the phenotypic complexity of many diseases, including NSCLC. These genomic approaches have shown great prom...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0037-z

    authors: Jolly Graham A,Potti A

    更新日期:2009-07-01 00:00:00

  • Second-line chemotherapy for non-small-cell lung cancer.

    abstract::Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consiste...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0016-x

    authors: Fossella FV

    更新日期:2000-01-01 00:00:00

  • Genetic polymorphism and cancer risk.

    abstract::Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0075-z

    authors: Clapper ML

    更新日期:2000-05-01 00:00:00

  • Management of primary intraocular lymphoma.

    abstract::Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin's lymphoma. PIOL typically presents as a vitritis that is unresponsive to corticosteroid t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0029-6

    authors: Kim SK,Chan CC,Wallace DJ

    更新日期:2005-01-01 00:00:00

  • Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.

    abstract:PURPOSE OF REVIEW:Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0693-y

    authors: Koshkin VS,Grivas P

    更新日期:2018-04-11 00:00:00

  • The clinical importance of quality-of-life scores in patients with skull base tumors: a meta-analysis and review of the literature.

    abstract::Health-related quality of life (QOL) outcomes are frequently used by clinicians, patients, and researchers for assessing the effectiveness of an intervention. Small differences in QOL may be statistically significant but their clinical relevance remains undefined. The smallest changes in QOL scores of the anterior sku...

    journal_title:Current oncology reports

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s11912-012-0222-3

    authors: Amit M,Abergel A,Fliss DM,Gil Z

    更新日期:2012-04-01 00:00:00

  • Immune Checkpoint Inhibitors in Gliomas.

    abstract:PURPOSE OF REVIEW:Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT FINDINGS:A limited body of preclin...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0586-5

    authors: Tan AC,Heimberger AB,Khasraw M

    更新日期:2017-04-01 00:00:00